Formulations of cardamonin

Topical cardamonin formulations address aged skin issues by enhancing skin resilience and elasticity through antioxidant and elastase inhibition, effectively addressing wrinkles and collagen degradation in aged skin.

WO2024233751A2PCT designated stage expired Publication Date: 2024-11-14DEBUT BIOTECHNOLOGY INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/028522
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-10
Filing Date
2024-05-09
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Aged skin experiences decreased keratinocyte proliferation, thinning, impaired barrier formation, and reduced collagen synthesis, leading to wrinkles, bruising, and decreased skin elasticity, with existing treatments lacking effective topical solutions for improving skin condition and appearance.

Method used

Topical formulations of cardamonin, dissolved in solvents like dimethyl isosorbide, are developed to enhance skin resilience, elasticity, and prevent damage, featuring antioxidant, elastase enzyme inhibition, and glycation inhibition properties, while being stable for extended storage periods.

Benefits of technology

The cardamonin formulations effectively improve skin appearance by reducing wrinkles, enhancing elasticity, and preventing damage through robust antioxidant and elastase inhibition activities, maintaining collagen network integrity and promoting skin resiliency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000010_0001
    Figure IMGF000010_0001
  • Figure IMGF000031_0001
    Figure IMGF000031_0001
  • Figure IMGF000011_0001
    Figure IMGF000011_0001
Patent Text Reader

Abstract

The invention provides compositions comprising cardamonin. The compositions of the invention may be administered topically, on the skin of the subject. The invention further provides methods of administration of compositions comprising cardamonin for amelioration or treatment of a. skin condition. The compositions of the invention may also be applied for improving the general appearance of the skin.
Need to check novelty before this filing date? Find Prior Art

Description

[0001]Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application FORMULATIONS OF CARDAMONIN I. FIELD OF THE INVENTION The invention is related to formulations of cardamonin and methods of using the^ formulations for topical conditions in a subject. II. BACKGROUND OF THE INVENTION Mammalian epidermis and its appendages (e.g., hair, nail, sebaceous and sweat glands) provide a barrier to keep harmful elements out of the body and essential body fluids in. As the^ first line of defense against the various physical traumas of the environment, the epidermis must protect itself as well as the underlying tissues. The epidermis is also exposed to mutagenic ultraviolet radiation. In nonhaired or sparsely haired regions such as most human skin, the epidermis is thicker than that of furred skin, and in these locations the skin functions primarily in a protective role. The constant assaults on the epidermis necessitate self-renewal, making^ the epidermis a prime example of an adult tissue that undergoes continual and rapid flux. Aged skin differs from youthful skin both in appearance and in function. The aged epidermis demonstrates decreased keratinocyte proliferation and is physically thinner, but mostly from decline of the rete ridges. In addition to thinning, aging slows wound healing, prolongs epidermal turnover, and impairs barrier formation. The skin appears thin, wrinkled,^ bruised, and rough. Wrinkling and bruising can also result from aging-related changes in the dermis. The dermis, too, is characteristically thinner in aged persons. Aged fibroblasts are less likely to synthesize normal amounts of collagen, elastin, laminin glycosaminoglycans, and fibronectin. The dermis can, in such cases, lack elasticity, strength, vessel support, remodeling abilities, and ground substances. For example, rete ridges can be effaced, and basal cells can^ no longer display villous projections into the dermis. Epidermal cell turnover is reduced up to 50% in the aged as compared to youth. For example, melanocyte numbers can decrease 8-20% per decade. There are fewer Langerhans cells in the aged, and those present are often functionally impaired. Collagen synthesis decreases, for example, up to 30% within 4 years of menopause in women. The^ numbers of collagen and elastic fibers are also decreased. The dermis can also become less echogenic to ultrasounds, consistent with changes in collagen and elastic tissues. 1 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application III. SUMMARY OF THE INVENTION The invention relates to compositions of cardamonin, and methods of using the compositions for treating, protecting, and / or altering (e.g., improving) the condition and / or aesthetic appearance of skin, including, for example, treating, preventing, ameliorating, reducing^ and / or eliminating fine lines and / or wrinkles of skin and / or improving the aesthetic appearance of fine lines and / or wrinkles of skin. In certain embodiments, the compositions of the invention lead to increase in skin and / or hair resiliency. In certain embodiments, the compositions of the invention lead to increase in elasticity of the skin. In certain embodiments, the compositions of the invention prevent skin damage. ^ Topical administration of compositions comprising cardamonin was not known in the field. In particular, the topical administration of cardamonin for improving the condition of skin, including enhancing the appearance of the skin, by topical administration of a composition comprising an effective amount of cardamonin was not known in the field. Beneficially, the invention recognizes, for the first time, that topical compositions comprising cardamonin may be^ used for improving the condition of the skin or for treatment of any ailment related to the skin of a subject. In one aspect, the invention includes a composition for topical administration comprising an effective amount of cardamonin. The effective amount of cardamonin is an amount of cardamonin that would be effective in treating, ameliorating, or otherwise impacting the underlying condition of the skin. The invention recognizes that cardamonin is poorly soluble or^ insoluble in water. The invention also recognizes that cardamonin is also poorly soluble or insoluble in oil, for example, cardamonin is insoluble in Helianthus Annuus (Sunflower) Seed Oil. In certain embodiments of the invention, cardamonin is dissolved in a solvent selected from a group consisting of: dimethyl isosorbide, ethoxydiglycol, isopropyl lauryl sarcosinate, pentylene glycol, propanediol, 1,2-hexanediol, and / or butylene glycol. In certain preferred embodiments,^ cardamonin is dissolved in dimethyl isosorbide. In certain embodiments, the composition comprising cardamonin is anhydrous. In certain embodiments, the composition comprises oil as the only solvent. In certain embodiments, cardamonin is dissolved in a solvent selected from a group consisting of: 1,2 heptanediol, 1,2 hexanediol, 1,2 propanediol, butylene glycol, C15-19 alkane,^ capric / caprylic triglyceride, dibutyl adipate, diisopropyl adipate, dimethyl isosorbide, dipropylene 2 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application glycol, ethanol, ethoxydiglycol, isoamyl laurate, isohexadecane, isopentyldiol, isopropyl myristate, isoproyl lauryl sarcosinate, jojoba oil, meadowfoam seed oil, mineral oil, neopentyl glycol diethylhexanoate, octyldodecanol, oleyl alcohol, pentylene glycol, phenylpropanol, polysorbate 20, propanediol, safflower seed oil, squalene, sunflower oil, t-butyl alcohol, tributyl^ citrate, tributyl-O-acetylcitrate, tri-C15-19 alkyl citrate, triethyl citrate, triethyl O-acetylcitrate, and triisostearin. Thus, in certain embodiments, the composition comprises an emulsion. Preferably, the emulsion is oil / water emulsion. In certain embodiments, the composition further comprises dimethyl isosorbide. In certain embodiments, cardamonin is dissolved in dimethyl isosorbide. The^ compositions of the invention are wherein the composition are stable under storage for at least 3 months. This is beneficial because the compositions of the invention may be stored prior to administration to the subjects. In certain embodiments, wherein the compositions of the invention have less than about 20% degradation when stored at 4 ^ or 25 ^ for two (2) months and one (1) month, respectively. In certain embodiments, the compositions of the invention have less than^ about 20% degradation when stored at 25 ^ for one (1) month. In certain embodiments, the compositions of the invention have less than about 20% degradation when stored at 4 ^ for two (2) months. In certain embodiments, the composition comprises cardamonin in a concentration of about 5 nM to about 2500 nM. In certain embodiments, the composition comprises cardamonin in a^ concentration of about 10 nM to about 2000 nM. In certain embodiments, the composition comprises cardamonin in a concentration of about 20nM nM to about 1000 nM. In certain embodiments, the composition comprises cardamonin in a concentration of about 10 nM to about 20 nM. In certain embodiments, in the compositions of the invention, cardamonin is present in a concentration of about 0.0001% to about 5.0% w / w. In certain other embodiments, cardamonin is^ present in a concentration of 0.0005% to about 2.0% w / w. In certain other embodiments, cardamonin is present in a concentration of 0.0007% to about 1.0% w / w. In certain other embodiments, cardamonin is present in a concentration of 0.001% to about 0.75% w / w. In certain other embodiments, cardamonin is present in a concentration of 0.001% to about 0.75% w / w. In certain other embodiments, cardamonin is present in a concentration of about 0.5% w / w. 3 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application In certain aspects, the compositions of the invention may be administered as a topical composition on the skin of the subject. The compositions of the invention may be included in any formulation suitable for topical administration. In certain embodiments, the composition of the invention is a fluid, emulsion, encapsulation, suspension, solid, semi-solid, jelly, paste, gel,^ hydrogel, ointment, lotion, emulsion, cream, foam, mousse, liquid, spray, suspension, dispersion, powder, aerosol, color cosmetic, and / or hair treatment. In certain embodiments, the compositions of the invention also include excipients. These excipients may be selected from a group consisting of: solvent, emulsifier, preservative, antioxidant, emollient, thickening agent, penetration enhancer, surfactant, diluent, filler, carrier, and / or pH control agent. In certain embodiments, the^ preservative in the composition is an antimicrobial preservative or chelating agent. In certain embodiments, the solvent of the invention is dimethyl isosorbide. The compositions of the invention may be prepared by various methods. As an example, the compositions may be prepared by dissolving, dispersing, etc. cardamonin as provided herein and optional excipients in a carrier (e.g., water, saline, aqueous dextrose, glycerol, glycols, ethanol^ or the like) or a solvent to form a solution, colloid, liposome, emulsion, complexes (including inclusion complexes), coacervate, or suspension. In certain embodiments, the compositions of the current invention can also contain additional excipients such as wetting agents, emulsifying agents, co-solvents, solubilizing agents, pH buffering agents, and the like (e.g., sodium acetate, sodium citrate, cyclodextrins and derivatives, sorbitan monolaurate, triethanolamine acetate,^ triethanolamine oleate, hydroxyethylpiperazine and the like). In certain embodiments, the compositions of the invention may further include one or more additional excipients selected from a group consisting of: carriers, excipients, or diluents including, but not limited to, absorbents, anti-irritants, antibacterials, anti-acne agents, antioxidants, coloring agents / pigments, emollients (moisturizers), emulsifiers, film-forming / holding agents, fragrances, leave-on exfoliants,^ prescription drugs, preservatives, scrub agents, silicones, skin-identical / repairing agents, slip agents, sunscreen actives, surfactants / detergent cleansing agents, penetration enhancers, and thickeners. In certain embodiments, the compositions of the invention comprise: cardamonin, in an oil / water emulsion, and a preservative. 4 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application In certain embodiments, the compositions of the invention comprise: cardamonin, in an oil / water emulsion, a solvent for solubilizing cardamonin, and a preservative. In certain embodiments, the compositions of the invention comprise cardamonin, in an oil / water emulsion, a solvent for solubilizing cardamonin, a diluent, and a preservative. ^ In certain embodiments, the compositions of the invention comprise: cardamonin, in an oil / water emulsion, a solvent for solubilizing cardamonin, a thickener, optionally a diluent, and a preservative. In certain embodiments, the compositions of the invention comprise: cardamonin, in an oil / water emulsion, a solvent for solubilizing cardamonin, and one or more excipients selected^ from the group consisting of: diluents, absorbents, antioxidants, emollients, emulsifiers, thickeners, surfactants, and / or preservatives. In certain embodiments, the excipients included in the composition are water, dimethyl isosorbide, glycerin, caprylic / capric triglyceride, propanediol, sunflower seed oil, ethoxydiglycol, squalane, sodium acrylate copolymer, cetearyl alcohol, phenoxyethanol, glyceryl stearate,^ capryloyl glycerin / sebacic acid copolymer, diheptyl succinate, naringenin, lecithin, decylene glycol, pentylene glycol, cetearyl glucoside, shea butter, palmitic acid, arachidyl alcohol, behenyl alcohol, arachidyl glucoside, phenethyl alcohol, 1,2-hexanediol, hydrogenated olive oil, olea europaea (olive) fruit oil, olea europaea (olive) oil unsponifiables, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, citric acid, sodium acetylated hyaluronate, sodium^ hyaluronate crosspolymer, sodium phytate, hydrolyzed sodium hyaluronate, and / or ethylhexylglycerin. In certain aspects, the invention provides that the compositions of the inventions are synergistic. The compositions provided in the invention are beneficial because of their enhanced stability due to the synergistic effects of the ingredients in the composition and the resulting^ stability and efficacy. In certain embodiments, the invention provides that the compositions of the invention are more efficacious and stable as compared to when they are administered or stored as individual ingredients. The compositions of the invention may also act synergistically when administered along with other therapies for treatment of the conditions described herein. 5 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application In certain aspects of the invention, the compositions comprising cardamonin demonstrate antioxidant activity. In certain embodiments, the compositions of the invention, the antioxidant activity of cardamonin is demonstrated at concentrations of about 0.00005% w / w or higher. Advantageously, the compositions of the invention comprising cardamonin, demonstrating^ antioxidant activity, are effective for treating and / or preventing oxidation damage. In certain embodiments, the compositions of the invention comprising cardamonin, demonstrating antioxidant activity, are effective for treatment of skin and / or hair damaged by reactive oxygen species and protection from other environmental aggressors that may damage the skin of the subject. In certain other embodiments, the compositions of the invention comprising cardamonin,^ demonstrating antioxidant activity, are effective for prevention of skin and / or hair damage by reactive oxygen species, including the damage caused by environmental aggressors. In certain aspects of the invention, the compositions comprising cardamonin demonstrate elastase enzyme inhibition. In certain embodiments, the compositions of the invention, the elastase enzyme inhibition activity of cardamonin is demonstrated at concentrations of about 0.05% w / w^ or higher. Advantageously, the compositions comprising cardamonin, demonstrating elastase enzyme inhibition activity, are effective for promoting the elasticity of the skin. In certain embodiments, the compositions of the invention comprising cardamonin, demonstrating elastase enzyme inhibition, are effective in reduction of fine lines and / or wrinkles in the skin. In certain embodiments, the compositions of the invention comprising cardamonin, demonstrating elastase^ enzyme inhibition, are effective in prevention of formation of fine lines and / or wrinkles in the skin. In certain aspects of the invention, the compositions comprising cardamonin demonstrate inhibition of glycation. In certain embodiments, the compositions of the invention, the glycation inhibition activity of cardamonin is demonstrated at concentrations of about 0.005% w / w or higher. Advantageously, the compositions comprising cardamonin, demonstrating glycation inhibition^ activity, are effective for supporting and promoting skin and / or hair resiliency. In certain aspects of the invention, the compositions comprising cardamonin promote skin lightening and / or brightening. In certain embodiments, the compositions comprising cardamonin at least a concentration of 0.01% w / w, have about 4% higher L value (reflecting the lightening of the skin), as compared to skin treated with a corresponding composition lacking cardamonin. 6 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application In certain aspects of the invention, the compositions comprising cardamonin promote skin lightening and / or brightening. In certain embodiments, the compositions comprising cardamonin at least a concentration of 0.01% w / w, have at least about 10% higher L value (reflecting the lightening of the skin), as compared to skin treated with a corresponding composition lacking^ cardamonin. In certain aspects of the invention, a composition comprising cardamonin modulates expression of one more genes that is related to a topical condition. In certain embodiments, administration of composition comprising cardamonin alters one or more of a function related with the modulated genes, wherein the one or more function is selected from the group consisting of:^ (i) lightening / brightening of the skin, (ii) formation of fines lines or wrinkles on the skin, (iii) inflammation, and (iv) collagen degradation. In certain embodiments, the one or more genes are selected from a group consisting of: (i) IL37, (ii) MMP1 and (iii) TNF. In certain embodiments, administration of a composition comprising cardamonin leads to down-regulation of IL37, TNF, and / or MMP1. ^ In certain embodiments, the administration of the compositions of the invention comprising cardamonin enhances anti-inflammatory activity. In certain embodiments, the administration of the compositions of the invention comprising cardamonin enhances the maintenance of collagen network to prevent formation of fine lines and / or wrinkles in the skin. In certain embodiments, the maintenance of collagen network is enhanced by prevention of degradation of collagen. ^ In certain embodiments, administration of a composition comprising cardamonin leads to downregulation of interleukin (IL37) and tumor necrosis factor (TNF). IL37 and / or TNF are involved in the inflammatory reactions in the body. Thus, downregulation of IL37 and / or TNF lead to an anti-inflammatory response. In certain embodiments, administration of a composition^ comprising cardamonin leads to at least about twenty (20) fold downregulation of IL37. In certain embodiments, administration of a composition comprising cardamonin leads to at least about ten (10) fold downregulation of TNF. In certain embodiments, administration of a composition comprising cardamonin leads to formation of fine lines and / or wrinkles on the skin. The prevention of formation of fine lines and / or 7 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application wrinkles on the skin, in part, is due increased collagen degradation. In certain embodiments, administration of a composition comprising cardamonin leads to formation downregulation of matrix metalloproteinase 1 (MMP1). The downregulation of expression and / or activity of MMP1 results in decrease in breakdown of collagen. In certain embodiments of the invention, the^ administration of the composition comprising cardamonin leads to at least about five (5) fold downregulation of MMP1. In certain embodiments, administration of a composition comprising cardamonin to a subject leads to the treatment of prevention of a topical condition of the subject through the modulation of levels of expression or activity of one or genes that may be involved in the topical^ condition. In certain embodiments, administration of a composition comprising cardamonin alters one or more of a function related with the modulated genes, wherein the one or more function is selected from the group consisting of: (i) collagen degradation and / or (ii) inflammation. IV. BRIEF DESCRIPTION OF DRAWINGS FIG.1A is a picture of the solution with 0.5% w / w cardamonin in oil / water emulsion.^ FIG.1B is a picture of 0.74% w / w cardamonin solubilized in dimethyl isosorbide. FIG.2 is a chart of stability of cardamonin in dimethyl isosorbide. FIG.3 provides the data pertaining to gene modulation expression. V. DETAILED DESCRIPTION ^ Cardamonin Cardamonin is a naturally occurring compound found in Aplinia katsumadai extract and other cardamom spice plants. Yoo et al., Cardamonin Inhibits Oxazolone-Induced Atopic Dermatitis by the Induction of NRF2 and the Inhibition of Th2 Cytokine Production. Antioxidants (Basel).2020 Sep 7;9(9):834. ^ The chemical structure of cardamonin is provided below: 8 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application Cardamonin may Cardamonin demonstrates anti-cancer properties. For example, cardamonin has been shown to selectively inhibit proliferation of melanoma cells without hindering viability of^ surrounding, healthy melanocytes and dermal fibroblasts. Berning L, et al. In vitro selective cytotoxicity of the dietary chalcone cardamonin (CD) on melanoma compared to healthy cells is mediated by apoptosis. PLoS One. 2019 Sep 25;14(9). Cardamonin has also demonstrated anticancer properties for other types of cancer, including pancreatic cancer. Goncalves et al., An Overview of Cardamonin, J. Med. Food, 2014, 17(6): 633-640. ^ Cardamonin also inhibits melanogenesis of human melanocytes via suppression of Wnt / B catenin signaling providing support for potential application as a lightening / brightening agent. Cho M, et al. Cardamonin suppresses melanogenesis by inhibition of Wnt / beta-catenin signaling. Biochem Biophys Res Commun. 2009, 18;390(3):500-5.^Cardamonin also inhibits lipid droplet accumulation, induces browning of adipocytes, and suppresses lipogenesis in normal adipocytes^ suggesting use as an anti-obesity and anti-cellulite treatment. Seo YJ, et al. Cardamonin suppresses lipogenesis by activating protein kinase A-mediated browning of 3T3-L1 cells. Phytomedicine. 2019, 65:153064. Compositions of cardamonin In one aspect, the invention provides compositions comprising cardamonin. In certain^ embodiments, the invention provides compositions comprising cardamonin that are suitable for administration on the skin of the subject. The invention recognizes that cardamonin is poorly soluble or insoluble in water. The invention also recognizes that cardamonin is also poorly soluble or insoluble in oil, for example, cardamonin is insoluble in Helianthus Annuus (Sunflower) Seed Oil. The invention recognizes 9 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application that the solvent used for preparing cardamonin compositions should be any solvent acceptable to be used in cosmetic formulations. In certain embodiments, cardamonin is dissolved in a solvent selected from a group consisting of: 1,2 heptanediol, 1,2 hexanediol, 1,2 propanediol, butylene glycol, C15-19 alkane,^ capric / caprylic triglyceride, dibutyl adipate, diisopropyl adipate, dimethyl isosorbide, dipropylene glycol, ethanol, ethoxydiglycol, isoamyl laurate, isohexadecane, isopentyldiol, isopropyl myristate, isoproyl lauryl sarcosinate, jojoba oil, meadowfoam seed oil, mineral oil, neopentyl glycol diethylhexanoate, octyldodecanol, oleyl alcohol, pentylene glycol, phenylpropanol, polysorbate 20, propanediol, safflower seed oil, squalene, sunflower oil, t-butyl alcohol, tributyl^ citrate, tributyl-O-acetylcitrate, tri-C15-19 alkyl citrate, triethyl citrate, triethyl O-acetylcitrate, and triisostearin. In certain preferred embodiments of the invention, cardamonin is dissolved in a solvent selected from a group consisting of: dimethyl isosorbide, ethoxydiglycol, isopropyl lauryl sarcosinate, pentylene glycol, propanediol, 1,2-hexanediol, and / or butylene glycol. In certain^ preferred embodiments, cardamonin is dissolved in dimethyl isosorbide. Table 1 provides the solubility data for cardamonin in several solvents. Table 1: Solubility of cardamonin Solubility S l As evident from the data provided above, cardamonin is soluble in dimethyl isosorbide.^ FIG.1B provides a picture of a solution of cardamonin dissolved in dimethyl isosorbide. 10 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application Thus, in certain embodiments, the composition comprises an emulsion. Preferably, the emulsion is oil / water emulsion. FIG.1A provides a picture of cardamonin formulated in oil / water emulsion. In certain embodiments, the composition further comprises dimethyl isosorbide. In certain^ embodiments, cardamonin is dissolved in dimethyl isosorbide. The compositions of the invention are wherein the composition is stable under storage for at least two (2) months. This is beneficial because the compositions of the invention may be stored prior to administration to the subjects. In certain embodiments, wherein the compositions of the invention have less than about 20% degradation when stored at 4 ^ or 25 ^ for 1 month or 2 months. FIG. 2 provides the data for^ stability cardamonin dissolved in dimethyl isosorbide. The invention beneficially provides that solutions of cardamonin dissolved in dimethyl isosorbide have increased solubility and are shelf stable. Since cardamonin is not soluble in sunflower oil and other commonly used solvents, the increased solubility in dimethyl isosorbide is surprising and unexpected. In certain embodiments, the composition comprises cardamonin in a concentration of about^ 5 nM to about 2500 nM. In certain embodiments, the composition comprises cardamonin in a concentration of about 10 nM to about 2000 nM. In certain embodiments, the composition comprises cardamonin in a concentration of about 20nM nM to about 1000 nM. In certain embodiments, the composition comprises cardamonin in a concentration of about 10 nM to about 20 nM. In certain embodiments, in the compositions of the invention, cardamonin is present in a^ concentration of about 0.0001% to about 5.0% w / w. In certain other embodiments, cardamonin is present in a concentration of 0.0005% to about 2.0% w / w. In certain other embodiments, cardamonin is present in a concentration of 0.0007% to about 1.0% w / w. In certain other embodiments, cardamonin is present in a concentration of 0.001% to about 0.75% w / w. In certain other embodiments, cardamonin is present in a concentration of 0.001% to about 0.75% w / w. In^ certain other embodiments, cardamonin is present in a concentration of about 0.5% w / w. In certain aspects, the compositions of the invention may be administered as a topical composition on the skin of the subject. The compositions of the invention may be included in any formulation suitable for topical administration. In certain embodiments, the composition of the invention is a fluid, emulsion, encapsulation, suspension, solid, semi-solid, jelly, paste, gel,^ hydrogel, ointment, lotion, emulsion, cream, foam, mousse, liquid, spray, suspension, dispersion, 11 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application powder, aerosol, color cosmetic, and / or hair treatment. In certain embodiments, the compositions of the invention also include excipients. These excipients may be selected from a group consisting of: solvent, emulsifier, preservative, antioxidant, emollient, thickening agent, penetration enhancer, surfactant, diluent, filler, carrier, and / or pH control agent. In certain embodiments, the^ preservative in the composition is an antimicrobial preservative or chelating agent. In certain embodiments, the solvent of the invention is dimethyl isosorbide. The compositions of the invention may be prepared by various methods. As an example, the compositions may be prepared by dissolving, dispersing, etc cardamonin as provided herein and optional excipients in a carrier (e.g., water, saline, aqueous dextrose, glycerol, glycols, ethanol^ or the like) or a solvent to form a solution, colloid, liposome, emulsion, complexes (including inclusion complexes), coacervate, or suspension. In certain embodiments, the compositions of the current invention can also contain auxiliary substances such as wetting agents, emulsifying agents, co-solvents, solubilizing agents, pH buffering agents, and the like (e.g., sodium acetate, sodium citrate, cyclodextrins and derivatives, sorbitan monolaurate, triethanolamine acetate,^ triethanolamine oleate, hydroxyethylpiperazine and the like). In certain embodiments, the compositions of the invention may further include one or more additional excipients selected from a group consisting of: carriers, excipients, or diluents including, but not limited to, absorbents, anti-irritants, antibacterials, anti-acne agents, antioxidants, coloring agents / pigments, emollients (moisturizers), emulsifiers, film-forming / holding agents, fragrances, leave-on exfoliants,^ prescription drugs, preservatives, scrub agents, silicones, skin-identical / repairing agents, slip agents, sunscreen actives, surfactants / detergent cleansing agents, penetration enhancers, and thickeners. Absorbents are substances which are added to topical products to take up water and oil- soluble dissolved or finely dispersed substances. Topical absorbents can also be used as thickeners^ in a wide variety of formulations including facial creams, lipsticks, shampoos and calamine lotions. In some embodiments, absorbents may include, but are not limited to, alcohol (ethyl alcohol, methanol, isopropyl alcohol, SD alcohol [especially denatured alcohol] and benzyl alcohol), alumina (aluminum oxide), aluminum chlorohydrate, aluminum hydroxide, aluminum magnesium silicate, aluminum silicate, aluminum starch octenylsuccinate, aluminum sulfate,^ ammonium chloride, bentonite, bismuth oxychloride, boron nitride, calcium carbonate, carnauba 12 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application wax, charcoal, China clay, clay, Copernicia cerifera wax, cornstarch, fuller's earth, hydrolyzed corn starch, iron powder, kaolin, lithium magnesium sodium silicate, magnesium, magnesium carbonate, magnesium hydroxide, montmorillonite, nylon-12, rice starch, silica, silicate, silk powder, silt, sodium carbonate, sodium polyacrylates, and zeolite. ^ Anti-Irritants are substances which are added to topical products to reduce inflammation, especially, the inflammation resulting from the application of the product itself. The excipients included as anti-irritants that perform the function of anti-irritants or anti-inflammatories may have more than one function. For example, many antioxidants also function as anti-irritants. In some embodiments, anti-irritants and / or antioxidants may include, but are not limited to, Acacia senegal,^ acetylsalicylic acid, Achillea millefolium, adenosine, citric acid, adenosine triphosphateAloe barbadensis, aloe barbadensis leaf juice extract, aloe extract, aloe juice, hydrogenated olive oil, hydrogenated palm glycerides, hydrolyzed silk, hydroquinone, aloe vera, and / or alpha bisabolol. In certain embodiments, the compositions of the invention may further include humectants. Humectants (or moisturizers) are important cosmetic ingredients that prevent loss of moisture^ thereby retaining the skin’s natural moisture. Some humectants also can actively attract moisture. In certain embodiments, the humectants may be selected from a group consisting of sodium hyaluronate, sodium acetylated hyaluronate, hydrolyzed sodium hyaluronate, propylene glycol, hexylene glycol, and butylene glycol. In certain embodiments, the compositions of the invention may further include slip agents.^ The term “slip agent” is used to describe a range of ingredients which can help other ingredients spread over the skin and penetrate into the skin. Slip agents can also have humectant (hygroscopic) properties. In some embodiments, slip agents may include, but are not limited to, amodimethicone, bis-PEG-18 methyl ether dimethyl silane, bis-phenylpropyl dimethicone, butylene glycol, cetyl dimethicone, cetyl dimethicone copolyol, cetyl PEG / PPG-10 / 1-dimethicone, cyclohexasiloxane,^ cyclomethicone, cyclopentasiloxane, cyclotetrasiloxane, decylene glycol, diisostearoyl trimethylolpropane siloxy silicate, dimethicone, dimethicone copolyol, dimethicone crosspolymer, dimethiconol, dipropylene glycol, hexylene glycol, hydrolyzed silk, isododecane, methicone, methyl trimethicone, methylsilanol mannuronate, methylsilanol PEG-7 glyceryl cocoate, Good, PEG-10 dimethicone, PEG-10 dimethicone / vinyl dimethicone crosspolymer, PEG-12^ dimethicone, PEG / PPG-18 / 18 dimethicone, PEG / PPG-20 / 15 dimethicone, pentylene glycol, 13 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application phenyl trimethicone, polymethylsilsesquioxane, PPG-3 benzyl ether myristate, silica dimethyl silylate, silk powder, siloxane, simethicone, sorbitol, stearyl dimethicone, stearyl methicone, triethoxycaprylylsilane, trimethylsiloxysilicate, xylitol, and zinc stearate. In certain embodiments, the compositions of the invention may further include diluents,^ and / or carriers. Diluents and / or carriers may include, but are not limited to, polyethylene glycols (such as PEG200, PEG300, PEG400, PEG540, PEG600, PEG1450 or mixtures thereof) and coconut oils (such as propylene glycol dicaprate, coco-caprylate / caprate, propylene glycol dicaprylate / dicaprate, caprylic / capric triglyceride, caprylic / capric / lauric triglyceride, caprylic / capric / linoleic triglyceride, tricaprin, tricaprylin, glyceryl trioleate, neopentyl glycol^ dicaprylate / dicaprate, caprylic / capric / palmitic / stearic triglceride, or mixtures thereof). In certain embodiments, the compositions of the invention may further include emollients. Emollients are supple, waxlike, lubricating, thickening substances which are added to cosmetic / dermatological products to prevent water loss and have a softening and soothing effect on the skin.^ In some embodiments, emollients may include, but are not limited to, 10-^ hydroxydecanoic acid, acetyl glyceryl ricinoleate, acetylated castor oil, acetylated hydrogenated cottonseed glyceride, acetylated lanolin,^ acetylated lanolin alcohol, acetylated palm kernel glycerides, agar, algae extract, algin, almond oil, squalane, squalene, Į-glucan oligosaccharide, amodimethicone, Anacystis nidulans extract, apricot kernel oil, arachidic acid, arachidonic acid, arachidyl alcohol, arachidyl propionate, C10-30 cholesterol / lanosterol esters, C12-15 alkyl benzoate,^ C12-18 acid triglyceride, C18-36 acid triglyceride, candelilla wax, Cannabis sativa L. oil, caprylic / capric triglyceride, caprylyl methicone, carrot oil, Carthamus tinctorius oil, Carya illinoensis oil, castor isostearate succinate, castor oil, Caulerpa taxifolia extract, and / or cephalin. In certain embodiments, the compositions of the invention may further include film-^ forming / holding agents. Film-Forming / Holding agents are substances which are added to cosmetic / dermatological products to help leave a pliable, cohesive, and continuous covering over the skin. This film has water-binding properties and leaves a smooth feel on skin. In some embodiments, film-forming / holding agents may include, but are not limited to, acrylate, acrylates copolymer, acrylates / C10-30 alkyl acrylate crosspolymer, acrylates / dimethicone copolymer, adipic^ acid / neopentyl glycol / trimellitic anhydride copolymer, allyl methacrylates crosspolymer, 14 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application carnauba wax, cellulose gum, Copernicia cerifera wax, dextrin, diisopropyl adipate, glyceryl polymethacrylate, hydrolyzed wheat protein, hydroxyethylcellulose, locust bean, neopentyl glycol diheptanoate, PEG-40 hydrogenated castor oil, polyacrylamide, polyacrylate-17, polyglucuronic acid, polyglyceryl methacrylate, polyisobutene, polymethyl methacrylate, polyquaternium-10,^ polyquaterniums, polyvinyl alcohol, polyvinylpyrrolidone, propylene carbonate, PVM / MA (polyvinyl methyl ether / maleic acid) decadiene crosspolymer, PVP [poly(vinylpyrrolidone)] copolymer, PVP / dimethylaminoethyl-methacrylate, sodium carbomer, sodium polyacrylate, styrene / acrylates copolymer, triethoxycaprylylsilane crosspolymer, VA (vinyl acetate) / crotonates, VA / crotonates copolymer, VP (vinylpyrrolidone) / eicosene copolymer, and VP / hexadecene^ copolymer. In certain embodiments, the compositions of the invention may further include excipients related to the fragrance of the formulation. Fragrance ingredients are a single or a blend of volatile and / or fragrant plant oils (or synthetically derived oils) that impart aroma and odor to cosmetic / dermatological products. The level of fragrance to use varies according to the product^ type. In some embodiments, the composition of the formulation may contain up to about 0.01% fragrance by weight. In some embodiments, fragrances (e.g., synthetic and fragrant plant extracts) may include, but are not limited to, Acacia farnesiana extract, Aerocarpus santalinus, amyl cinnamate, amyl salicylate, amyris oil, Anethum graveolens, Angelica archangelica root oil, anisaldehyde, anise, balm mint extract, balsam peru, bay leaf oil, bergamot oil, bitter orange^ flower, bois de rose oil, bois oil, Boswellia carterii, butylphenyl methylpropional, cananga extract, Cananga odorata, cardamom, cedarwood, cherry extract, Citrus aurantifolia, Citrus aurantium, Citrus aurantium extract, Citrus medica limonium, clary oil, Commiphora myrrha extract, coriander, Cucurbitea peponis, cyclamen aldehyde, dill extract, ethyl vanillin, eugenol, farnesol, farnesyl acetate, Ferula galbaniflua, fir needle oil,^ floralozone, Foeniculum vulgare extract, frankencense extract, galbanum, Gardenia florida extract, grapefruit oil, guaiac wood, Guaiacum officinale, hedione, hexyl cinnamal, hyssop, Illicium vernum, Iris florentina extract, jasmine oil, Jasminium grandiflorum, jonquil extract, Laurus nobilis, lauryl lactate, lavandin oil, Lavandula angustifolia, Lavandula officinalis, lavender extract and oil, lemon, lemon balm, lemongrass oil, Levisticum officinale root extract,^ lime oil and extract, limonene, linalool, Litsea cubeba, mandarin orange oil or extract, 15 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application marjoram, Melissa officinalis, Mentha piperita, Mentha spicata, Mentha viridis, menthol, menthone, menthoxypropanediol, and menthyl lactate. In certain embodiments, the composition of the invention may further include preservatives. Preservatives are substances which prevent bacterial, microbial or fungal^ contamination of cosmetic / dermatological products thereby increasing the product's shelf life and consumer safety. Some of these agents also have stabilizing effects able to preserve the function of various active ingredients including anti-oxidants (vitamins), emulsifiers and surfactants. In some embodiments, preservatives may include, but are not limited to, 1,2-hexanediol, benzoic acid, benzothonium chloride, borax, bronopol, butylparaben, caprylyl glycol, chlorophene,^ chloroxylenol, chlorphenesin, decylene glycol, dehydroacetic acid, diazolidinyl urea, DMDM hydantoin, ethylhexylglycerin, ethylparaben, formaldehyde-releasing preservative, Germaben II, hoelen, hydroxyacetophenone, imidazolidinyl urea, iodopropynyl butylcarbamate, isobutylparaben, methylchloroisothiazolinone, methyldibromo glutaronitrile, Methylisothiazolinone, methylparaben, o-cymen-5-ol, phenoxyethanol, phenoxyisopropanol,^ phytosphingosine, polyaminopropyl biguanide, potassium sorbate, propylparaben, quaternium-15, sodium benzoate, sodium citrate, sodium dehydroacetate, sodium hexametaphosphate, sodium hydroxymethylglycinate, phenethyl alcohol, sodium lactobionate, sodium metabisulfite, sodium sulfite, sorbic acid, and styrax benzoin. In certain aspects of the invention, the pharmaceutical composition is an emulsion. The^ emulsion compositions of the invention may further include emulsifiers. Emulsifiers are substances which are added to cosmetic / dermatological products to help keep unlike ingredients (such as oil and water) from separating in an emulsion. There are 2 types of emulsifiers. Oil-in- water (o / w) emulsifiers keep oil drops packed in water, while water-in-oil (w / o) emulsifiers keep water drops packed in oil. W / O emulsifiers are used for a fatty feel (e.g. night & sun protection^ creams). O / W emulsifiers are used more in moisturizing products (e.g. body lotions, day creams). In certain embodiments, the compositions of the invention may further include surfactants. Surfactants are compounds that lower surface tension or interfacial tension. Reducing the surface tension allows a liquid to spread easier while reducing the interfacial tension (interfacial meaning between two faces) between water and an oil / lipid allows them to mix. Surfactants may have a be^ anionic, amphoteric, non-ionic, and / or quaternary agents. Surfactants form the base of all personal 16 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application cleansing products and can also have wetting, conditioning, defatting, emulsifying, & thickening effects. In some embodiments, emulsifiers, surfactants, and detergents may include, but are not limited to, ammonium laureth sulfate, ammonium lauryl sulfate, arachidyl glucoside, behenic acid, bis-PEG-18 methyl ether dimethyl silane, C20-40 pareth-40, cocamidopropyl betaine,^ cocamidopropyl dimethylamine, cocamidopropyl hydroxysultaine, coco-glucoside, coconut oil, decyl glucoside, dicetyl phosphate, dihydrocholeth-30, disodium cocoamphodiacetate, disodium cocoyl glutamate, disodium lauraminopropionate, glyceryl behanate, hydrogenated vegetable glycerides citrate, isohexadecane, isostearamide DEA, lauramphocarboxyglycinate, laureth-23, laureth-4, laureth-7, lauryl PEG-9 polydimethylsiloxyethyl dimethicone, lauryl alcohol, lauryl^ glucoside, magnesium laureth sulfate, magnesium oleth sulfate, myristic acid, nonoxynols, oleic acid, oleth 10, palm kernel acid, palmitic acid, PEG-60 almond glycerides, PEG-75 shea butter glycerides, PEG 90M, PEG-10 dimethicone, PEG-10 dimethicone / vinyl dimethicone crosspolymer, PEG-10 rapeseed sterol, PEG-100 stearate, PEG-12 dimethicone, PEG-120 methyl glucose dioleate, PEG-20 methyl glucose sesquistearate, PEG-40 stearate, PEG-60 hydrogenated^ castor oil, PEG-7 glyceryl cocoate, PEG-8, PEG-80 sorbitan laurate, PEG / PPG-17 / 6 copolymer (polyethylene glycol / polypropylene glycol-17 / 6 copolymer), PEG / PPG-18 / 18 dimethicone, PEG / PPG-20 / 15 dimethicone, poloxamer 184, Poloxamer 407, poloxamers, polyglyceryl-3 beeswax, polyglyceryl-4 isostearate, polyglyceryl-6 isostearate, polysorbate 20, polysorbate 60, polysorbate 80, potassium cetyl phosphate, potassium hydroxide, potassium myristate, PPG-12^ buteth-16, PPG-26-Buteth-26, Salvia officinalis, Saponaria officinalis extract, soapwort, sodium C14-16 olefin sulfonate, sodium cetearyl sulfate, sodium cocoamphoacetate, sodium cocoate, sodium cocoyl glutamate, sodium cocoyl isethionate, sodium dilauramidoglutamide lysine, sodium hexametaphosphate, sodium hydroxide, sodium laureth sulfate, sodium laureth-13 carboxylate, sodium lauroamphoacetate, sodium lauroyl lactylate, sodium lauroyl sarcosinate,^ sodium lauryl glucose carboxylate, sodium lauryl sulfate, sodium methyl cocoyl taurate, sodium methyl taurate, sodium myreth sulfate, sodium palm kernelate, sodium palmate, sodium PEG-7 olive oil carboxylate, sodium trideceth sulfate, steareth-20, TEA-lauryl sulfate (triethanolamine- lauryl sulfate), and tribehenin PEG-20 esters. In certain embodiments, the compositions of the invention may further include one or more^ thickeners. Thickeners are substances which are added to cosmetic / dermatological products to 17 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application enhance the consistency, volume and viscosity of cosmetic products, thereby providing more stability and better performance. While some thickeners have also emulsifying or gelling properties, the majority of thickeners have the ability to retain water on the skin and act therefore as moisturizers. Thickeners can be completely natural like waxes but also synthetic or semi-^ synthetic. In some embodiments, thickeners may include, but are not limited to, Acacia senegal, acetyl glyceryl ricinoleate, acetylated castor oil, acetylated hydrogenated cottonseed glyceride, acetylated palm kernel glycerides, acrylates / steareth-20 methacrylate copolymer, agar, Ahnfeltia concinna extract, ahnfeltia extract, Alaria esculenta, algae, algae extract, algin, alkyloamides, Althaea rosea, Althea officinalis, alumina, aluminum hydroxide, aluminum stearate,^ ammonium acryloyldimethyltaurate / VP copolymer, Anacystis nidulans extract, arachidic acid, arachidonic acid, arachidyl alcohol, arachidyl propionate, arrowroot, artemia extract, Ascophyllum nodosum, ascorbyl methylsilanol pectinate, Asparagopsis armata extract, beeswax, behenic acid, behentrimonium chloride, behenyl alcohol, bis-diglyceryl polyacyladipate, bismuth oxychloride, C12-15 alkyl benzoate, C12-18 acid triglyceride, C13-14 isoparaffin, C18-36 acid triglyceride, candelilla^ wax, caprylic / capric triglyceride, carbomer, carbopol, carnauba wax, carrageenan, Caulerpa taxifolia extract, cellulose, Cellulose gum, cephalin, Cera alba, ceresin, ceteareth-20, cetearyl alcohol, cetearyl ethylhexanoate, cetearyl glucoside, cetearyl octanoate, cetyl alcohol, cetyl dimethicone copolyol, cetyl hydroxyethylcellulose, cetyl palmitate, cetyl PEG / PPG-10 / 1- dimethicone, chlorella, Chondrus crispus, cocamide DEA and MEA, cocoglycerides, Codium^ tomentosum extract, Copernicia cerifera wax, Corallina officinalis extract, Corallina , DEA oleth- 10 phosphate, diethanolamine (DEA), di-PPG-3 myristyl ether adipate, dimethicone crosspolymer, dimethicone / vinyl dimethicone crosspolymer, polyacrylate crosspolymer, and / or dimer dilinoleyl dimer dilinoleate. In certain embodiments, the compositions of the invention may further include one or more^ chelators. Chelating agents are any of numerous ingredients that bind with metal ions or metallic compounds, preventing them from adhering to a surface (such as skin, hair, or clothing) or causing contamination, such as in the case of trace amounts of iron. In some embodiments, chelators may include, but are not limited to tetrasodium EDTA, sodium phytate, and / or teathydroxypropyl ethylenediamine. 18 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application In certain embodiments, the excipients included in the composition are water, dimethyl isosorbide, glycerin, caprylic / capric triglyceride, propanediol, sunflower seed oil, ethoxydiglycol, squalane, sodium acrylate copolymer, cetearyl alcohol, phenoxyethanol, glyceryl stearate, capryloyl glycerin / sebacic acid copolymer, diheptyl succinate, naringenin, lecithin, decylene^ glycol, pentylene glycol, cetearyl glucoside, shea butter, palmitic acid, arachidyl alcohol, behenyl alcohol, arachidyl glucoside, phenethyl alcohol, 1,2-hexanediol, hydrogenated olive oil, olea europaea (olive) fruit oil, olea europaea (olive) oil unsponifiables, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, citric acid, sodium acetylated hyaluronate, sodium hyaluronate crosspolymer, sodium phytate, hydrolyzed sodium hyaluronate, and / or^ ethylhexylglycerin. Table 2 provides a list of excipients, along with their approximate concentrations, that may be used in the exemplary compositions of the invention. is provided below: Table 2: Excipients in an exemplary composition: Ingredient %w / w Water 40 - 80 19 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application Behenyl Alcohol 0 - 1 Arachidyl Glucoside 0 - 1 Cardamonin for treatment of topical conditions: Advantageously, it was discovered that cardamonin impacts the genes and signaling pathways involved in several topical conditions. In one aspect, the invention provides methods of^ using the compositions for treating, protecting, and / or altering (e.g., improving) the condition and / or aesthetic appearance of skin, including, for example, treating, preventing, ameliorating, reducing and / or eliminating fine lines and / or wrinkles of skin and / or improving the aesthetic appearance of fine lines and / or wrinkles of skin. In certain embodiments, the compositions of the invention lead to increase in skin and / or hair resiliency. In certain embodiments, the compositions^ of the invention lead to increase in elasticity of the skin. In certain embodiments, the compositions of the invention prevent skin damage. In one aspect, the invention includes a composition for topical administration comprising an effective amount of cardamonin. The effective amount of cardamonin is an amount of cardamonin that would be effective in treating, ameliorating, or otherwise impacting the^ underlying condition of the skin. In certain aspects of the invention, the compositions comprising cardamonin promote skin lightening and / or brightening. In certain embodiments, the compositions comprising cardamonin 20 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application at least a concentration of 0.01% w / w, have about 4% higher L value (reflecting the lightening of the skin), as compared to skin treated with a corresponding composition lacking cardamonin. In certain aspects of the invention, the compositions comprising cardamonin demonstrate antioxidant activity. In certain embodiments, the compositions of the invention, the antioxidant^ activity of cardamonin is demonstrated at concentrations of about 0.00005% w / w or higher. Advantageously, the compositions of the invention comprising cardamonin, demonstrating antioxidant activity, are effective for treating and / or preventing oxidation damage. In certain embodiments, the compositions of the invention comprising cardamonin, demonstrating antioxidant activity, are effective for treatment of skin and / or hair damaged by reactive oxygen^ species and protection from other environmental aggressors that may damage the skin of the subject. In certain other embodiments, the compositions of the invention comprising cardamonin, demonstrating antioxidant activity, are effective for prevention of skin and / or hair damage by reactive oxygen species, including the damage caused by environmental aggressors. As demonstrated from the data provided in Examples 2 and 3, compositions comprising^ cardamonin are effective in demonstrating robust antioxidant activity in both aqueous and organic solvent systems. The IC50 values for antioxidant activity calculated in aqueous solvent system was 0.0006% w / w. These results demonstrate that compositions comprising cardamonin have robust antioxidant activity. In certain embodiments, the compositions comprising cardamonin are useful in treatment of conditions caused by oxidation or excessive oxidation in the skin of the subject. In^ certain embodiments, the compositions comprising cardamonin are administered for treatment and / or prevention of skin or hair damage by reaction oxygen species and protection from environmental aggressors. In certain aspects of the invention, the compositions comprising cardamonin demonstrate elastase enzyme inhibition. In certain embodiments, the compositions of the invention, the elastase^ enzyme inhibition activity of cardamonin is demonstrated at concentrations of about 0.001% w / w or higher. As evident from the data provided in Example 4, compositions comprising cardamonin have robust elastase enzyme inhibition activity. Indeed, the calculated IC50 value for elastase inhibition by compositions comprising cardamonin is 0.011% w / w. 21 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application Advantageously, the compositions comprising cardamonin, demonstrating elastase enzyme inhibition activity, are effective for promoting the elasticity of the skin. In certain embodiments, the compositions of the invention comprising cardamonin, demonstrating elastase enzyme inhibition, are effective in reduction of fine lines and / or wrinkles in the skin. In certain^ embodiments, the compositions of the invention comprising cardamonin, demonstrating elastase enzyme inhibition, are effective in prevention of formation of fine lines and / or wrinkles in the skin. In certain aspects of the invention, the compositions comprising cardamonin demonstrate inhibition of glycation. In certain embodiments, the compositions of the invention, the glycation inhibition activity of cardamonin is demonstrated at concentrations of about 0.0005% w / w or^ higher. As evident from the data provided in Example 5, compositions comprising cardamonin have robust glycation inhibition. Indeed, the calculated IC50 value for glycation inhibition by compositions comprising cardamonin is 0.0074% w / w. Advantageously, the compositions comprising cardamonin, demonstrating glycation inhibition activity, are effective for supporting and promoting skin and / or hair resiliency. ^ Genetic expression and / or activity modulation In certain aspects of the invention, a composition comprising cardamonin modulates expression of one more genes that is related to a topical condition. In certain embodiments, administration of composition comprising cardamonin alters one or more of a function related with the modulated genes, wherein the one or more function is selected from the group consisting of:^ (i) lightening / brightening of the skin, (ii) formation of fines lines or wrinkles on the skin, (iii) inflammation, (iv) melanin synthesis, and (v) collagen degradation. In certain embodiments, the one or more genes are selected from a group consisting of: (i) IL37, (ii) MMP1 and (iii) TNF. In certain embodiments, administration of a composition comprising cardamonin leads to down-regulation of IL37, TNF, and / or MMP1. ^ In certain embodiments, the administration of the compositions of the invention comprising cardamonin enhances anti-inflammatory activity. This enhancement of anti-inflammatory activity of compositions comprising cardamonin may have beneficial effects on the condition and / or appearance of the skin. In certain embodiments, the administration of the compositions of the 22 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application invention comprising cardamonin enhances the maintenance of collagen network to prevent formation of fine lines and / or wrinkles in the skin. In certain embodiments, administration of a composition comprising cardamonin leads to downregulation of interleukin (IL37) and tumor necrosis factor (TNF). IL37 and / or TNF are^ involved in the inflammatory reactions in the body. Thus, downregulation of IL37 and / or TNF lead to an anti-inflammatory response. In certain embodiments, administration of a composition comprising cardamonin leads to at least about twenty (20) fold downregulation of IL37. In certain embodiments, administration of a composition comprising cardamonin leads to at least about ten (10) fold downregulation of TNF. ^ In certain embodiments, administration of a composition comprising cardamonin leads to formation of fine lines and / or wrinkles on the skin. The prevention of formation of fine lines and / or wrinkles on the skin, in part, is due increased collagen degradation. In certain embodiments, administration of a composition comprising cardamonin leads to formation downregulation of matrix metalloproteinase 1 (MMP1). The downregulation of expression and / or activity of MMP1^ results in decrease in breakdown of collagen. In certain embodiments of the invention, the administration of the composition comprising cardamonin leads to at least about five (5) fold downregulation of MMP1. In certain embodiments, administration of a composition comprising cardamonin to a subject leads to the treatment of prevention of a topical condition of the subject through the^ modulation of levels of expression or activity of one or genes that may be involved in the topical condition. In certain embodiments, administration of a composition comprising cardamonin alters one or more of a function related with the modulated genes, wherein the one or more function is selected from the group consisting of: (i) collagen degradation and / or (ii) inflammation. In certain embodiments, administration of a composition comprising cardamonin to a^ subject leads to the treatment of prevention of a topical condition of the subject through the modulation of levels of expression or activity of one or genes that may be involved in the topical condition. In certain embodiments, administration of a composition comprising cardamonin alters one or more of a function related with the modulated genes, wherein the one or more function is selected from the group consisting of: (i) maintenance of skin barrier, (ii) collagen expression, (iii) 23 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application collagen degradation, (iv) inflammation, (v) tissue atrophy, (vi) muscle loss, and (vii) melanin production. Treatment of topical conditions The current invention recognizes that the compositions comprising cardamonin is^ beneficial for treating, protecting and / or improving the condition and / or aesthetic appearance of skin. For example, the compositions of the invention may be effective for altering the aesthetic appearance of skin associated with or affected by, or for treating or preventing, fine lines and / or wrinkles of skin caused by, for example, cellular senescence, environmental damage or dermatoheliosis. The invention also provides methods for stimulating skin cell renewal, increasing^ cell or tissue regeneration, promoting fibroblast proliferation and synthesizing elastin, collagen, proteoglycans, and / or new connective tissue, thereby reducing or improving the appearance of wrinkles, restoring elasticity, resiliency, and / or suppleness to the skin. The compositions of the invention provided herein can be useful for improving the aesthetic appearance of skin. Such improvements can include, but are not limited to, all outward^ visibly and tactilely perceptible manifestations as well as any other macro or micro effects due to skin aging and damage. Such manifestations and effects can be induced or caused by intrinsic factors and / or extrinsic factors, e.g., chronological aging, environmental damage, climate, sun (UV) exposure, smoking, drugs, alcohol consumption, jetlag, night work, changes in circadian rhythm, pregnancy, menopause, genetic factors, nutritional factors and / or deficiencies,^ dehydration, stress, allergies (e.g., to plants, animals, medications, and other substances), exposure to industrial and / or household chemicals, indoor heating and cooling, various disorders and diseases such as arteriosclerosis, diabetes, heart disease, liver disease, and obesity, thinning of the outer layer of skin, decreases in the number of pigment-containing cells, increases in the size of pigment-containing cells, changes in the connective tissue, and reduction in the strength and^ elasticity of the skin. The aesthetic appearance of skin can be improved, for example, by improving the appearance of skin associated with or affected by one or more of wrinkles, dry skin, sensitive skin; wrinkling and sagging; acne; vitiligo (skin condition in which there is a loss of brown color (pigment) from areas of skin); fine lines, wizened skin, thinning of the dermis, the degradation of 24 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application collagen fibers, flaccid skin, thinned skin, and skin exposed to ultraviolet radiation. In some embodiments, the compositions of the invention can improve the aesthetic appearance of skin by decreasing the appearance of fine lines in the skin; creating a more youthful appearance of the skin; decreasing bags and / or rings around the eyes; increasing or restoring the elasticity, resiliency,^ and / or suppleness of the skin; increasing the apparent thickness, elasticity, flexibility, radiance, glow, and plumpness of the skin; improving the fineness of the skin texture; improving the appearance of wrinkles, lined, dry, flaky, aged, and / or photodamaged skin; treating or preventing photodamaged skin; reducing the signs of skin aging; reducing the appearance of hyperpigmentation; treating or preventing hyperpigmentation; treating or preventing pigment^ deposition in the skin (e.g., that caused by UV exposure); reducing the appearance of skin discolorations; and whitening, lightening, and / or bleaching the skin. In certain embodiments, the compositions may be used for care, treatment, cleansing, and / or protective products for facial or body skin; anti-wrinkle or anti-aging compositions; skin firming compositions; skin lightening compositions; compositions for^ irritated skin; sunscreen compositions, artificial tanning (self-tanning) compositions or after-sun care compositions; scalp care compositions; shaving preparation compositions; depilatory compositions; or make-up products for the skin of the face or body. In certain embodiments, the compositions comprising cardamonin are administered for altering the aesthetic appearance of skin associated with or affected by, or treating or preventing,^ a skin condition / disorder (e.g., a skin condition / disorder accompanied with a loss of skin elasticity). In certain embodiments, the compositions comprising cardamonin are administered for improving the barrier function and viability of the skin. In certain embodiments, the compositions comprising cardamonin are administered for^ altering the aesthetic appearance of skin associated with or affected by wrinkling, sagging, and / or a loss of skin elasticity. In certain embodiments, the compositions comprising cardamonin are administered for altering the aesthetic appearance of skin associated with or affected by deteriorations in skin viscoelasticity. 25 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application In certain embodiments, the compositions comprising cardamonin are administered for altering the aesthetic appearance of skin associated with or affected by one or more of wrinkles and / or fine lines, wizened skin, a lack of elasticity and / or of tonus of the skin, thinning of the dermis, degradation of collagen fibers, flaccid skin, thinned skin, and the internal degradation of^ the skin following exposure to ultraviolet radiation. In certain embodiments, the compositions comprising cardamonin are administered for decreasing the appearance of fine lines and / or wrinkles in the skin. In certain embodiments, the compositions comprising cardamonin are administered for decreasing the appearance of bags and / or rings around the eyes. ^ In certain embodiments, the compositions comprising cardamonin are administered for reducing the appearance of hyperpigmentation. In certain embodiments, the compositions comprising cardamonin are administered for improving or increasing one or more of the thickness, elasticity, flexibility, radiance, glow, and plumpness of the skin. ^ In certain embodiments, the compositions comprising cardamonin are administered for improving the fineness of skin texture. In certain embodiments, the compositions comprising cardamonin are administered for improving the appearance of wrinkled, lined, dry, flaky, aged or photodamaged skin. In certain embodiments, the compositions comprising cardamonin are administered for^ altering the aesthetic appearance of skin associated with or affected by skin discolorations. Methods of Administration: In one aspect, the invention provides methods of administration of the compositions comprising cardamonin. In certain embodiments, the invention the compositions of the invention are designed for topical administration. ^ In certain embodiments, the compositions of the invention may be administered as a topical composition on the skin of the subject. The compositions of the invention may be included in any formulation suitable for topical administration. In certain embodiments, the composition of the 26 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application invention is a fluid, emulsion, encapsulation, suspension, solid, semi-solid, jelly, paste, gel, hydrogel, ointment, lotion, emulsion, cream, foam, mousse, liquid, spray, suspension, dispersion, powder, aerosol, color cosmetic, and / or hair treatment. In certain other embodiments, the compositions comprising cardamonin may be prepared^ and used in the form of an aerosol spray, cream, emulsion, solid, liquid, dispersion, foam, oil, gel, lotion, mousse, ointment, powder, patch, pomade, solution, pump spray, stick, towelette, soap, or other forms commonly employed in the art of topical administration and / or cosmetic and skin care formulation. The compositions can be in an emulsion form. In addition, compounds provided herein used in the compositions provided herein can be used in color cosmetic compositions such^ as foundation makeups, blushes, eyeshadows, mascaras, concealers, eyeliners, lip colors, nail colors, and so on. Other cosmetic compositions can include perfumes, lipsticks, fingernail and toenail polish, eye and facial makeup, towelettes, deodorants, hand sanitizer, baby products, bath oils, bubble baths, and butters. In certain embodiments, the compositions comprising cardamonin are administered over^ an area of about 1.0 ^g / cm2to about 100 ^g / cm2. In certain embodiments, the compositions comprising cardamonin are administered for a duration till the desired impact in amelioration or prevention of a topical condition is realized. In certain embodiments, the composition comprising cardamonin comprises an effective amount of cardamonin. The effective amount of cardamonin is an amount of cardamonin that results in the^ desired result in the condition of the skin. In certain embodiments, the composition comprising cardamonin is administered once a day. In certain embodiments, the composition comprising cardamonin is administered twice a day. In certain embodiments, the composition comprising cardamonin is administered thrice a day. In certain embodiments, the composition comprising cardamonin is administered once every two days. In certain embodiments, the composition^ comprising cardamonin is administered once every three days. Examples: Example 1: Exemplary composition comprising cardamonin: Table 3 provides an exemplary formulation of cardamonin: 27 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application Table 3: Exemplary composition comprising cardamonin: Ingredient %w / w Water 61.7528 28 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application Example 2: ABTS antioxidant assay: The 2,2'-Azinobis [3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt (ABTS) antioxidant assay is designed to evaluate the antioxidant activity of compositions comprising cardamonin in an aqueous medium. ^ ABTS+ solution is generated as a free radical and used to measure relative ability of a compound to scavenge free radicals. Reduction of the absorbance at 734 nm was standardized to solvent control as an indication of ABTS+ scavenging. Table 4, provided below, demonstrates the results from these experiments: Table 4: ABTS (aqueous antioxidant assay) radical inhibition Cardamonin % Radical n ntr ti n (% / ) Inhibiti n ^ As evident from the results provided in Table 4 above, compositions comprising cardamonin demonstrate antioxidant activity at concentrations at low as 0.00008% w / w in aqueous systems. The calculated IC50 value is: 0.0006% w / w. Example 3: DPPH Antioxidant Activity assay ^ The 2,2-diphenyl-1-picrylhydrazyl (DPPH) antioxidant assay is designed to evaluate the antioxidant activity of compositions comprising cardamonin in an organic medium. 2,2-diphenyl-1-picrylhydrazyl (DPPH) is a stable free radical used to evaluate free radical scavenging capacity of a material. In the presence of an antioxidant DPPH is reduced, resulting in the formation of a colorless solution. Reduction of absorbance at 517 nm is standardized to^ solvent control as an indication of DPPH scavenging. Table 5, provided below, provides the antioxidant activity data. 29 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application Table 5: DPPH Radical Inhibition Cardamonin concentration % Radical Inhibition (%w / w) As evident from the results provided in Table 5 above, compositions comprising cardamonin demonstrate antioxidant activity at concentrations at low as 0.15% w / w in organic^ solvent systems. Example 4: Elastase enzyme inhibition: The assay was conducted to evaluate the elastase enzyme inhibition activity of compositions comprising cardamonin. Neutrophil infiltration and neutrophil elastase are both increased in the skin in response to^ UV stress. Neutrophil elastase has been shown to activate MMP-1 and MMP-2 collagenase in response to low dose UV exposure, harming the extracellular matrix and contributing to photoaging and wrinkle formation. The activity of elastase can be further upregulated in the presence of reactive oxygen species. Therefore, inhibition of this enzyme, particularly in combination with antioxidant activity, is effective in delaying wrinkle development and aiding in^ maintaining skin integrity. This assay is measures release of 4-nitroaniline from an Me-Suc-Ala- Ala-Pro-Val-pNA by human neutrophil elastase and can be quantified at 405 nm by comparing to solvent control. Table 6 provides the elastase inhibition activity of compositions comprising cardamonin: Table 6: Elastase enzyme inhibition ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application 0.0039 28.01 As evident from the data provide in Table 6, compositions comprising cardamonin inhibits elastase enzyme activity as low at 0.001% w / w. The calculated IC50 value is: 0.011% w / w. ^ Example 5: Glycation inhibition assay: The assay was conducted to evaluate the glycation inhibition activity of compositions comprising cardamonin. Nonenzymatic glycation can occur when glucose reacts with proteins, forming a Schiff base intermediate that subsequently undergoes Amadori rearrangement to form glycosylated^ proteins, when they react with skin proteins to form Advanced Glycation End products (AGE). AGE formation can result in loss of skin elasticity and impaired cellular function. The glycation inhibition ability of a compound is measured by change in fluorescence at excitation / emission of 360 nm / 420 nm relative to solvent control. Table 7 provides the data for glycation inhibition. ^ Table 7: Glycation Inhibition Cardamonin concentration % Enzyme Inhibition 31 ^ Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application As evident from the data provided in Table 7, compositions comprising cardamonin inhibits glycation as low as 0.0005% w / w. The IC50 value calculated for glycation inhibition is 0.0074%. Example 6: Preclinical analysis of lightening and / or brightening effects of compositions ^ comprising cardamonin: The experiment was designed to evaluate the impact of compositions comprising cardamonin on skin lightening and / or brightening. In preclinical analysis, conducted on in vitro skin tissues, the compositions comprising cardamonin resulted in lightening and / or brightening of the skin. ^ Table 8: Lightening and / or Brightening of skin tissues Cardamonin Concentration L value % / Incorporation by Reference References and citations to other documents, such as patents, patent applications, patent publications, journals, books, papers, web contents, publicly accessible databases, have been made^ throughout this disclosure. All such documents are hereby incorporated herein by reference in their entirety for all purposes. Equivalents Various modifications of the invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the full^ contents of this document, including references to the scientific and patent literature cited herein. The subject matter herein contains important information, exemplification and guidance that can be adapted to the practice of this invention in its various embodiments and equivalents thereof. 32 ^

Claims

Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application CLAIMS:

1. A composition for topical administration comprising an effective amount of cardamonin.

2. The composition of claim 1, wherein the composition comprises an emulsion.

3. The composition of claim 2, wherein the emulsion is an oil / water emulsion.

4. The composition of claim 1, wherein the composition further comprises dimethyl isosorbide.

5. The composition of claim 1, wherein the cardamonin is dissolved in dimethyl isosorbide.

6. The composition of claim 5, wherein the composition is stable under storage for at least three (3) months.

7. The composition of claim 5, wherein the composition has less than about 10% degradation when stored at 4 ^ for three (3) months.

8. The composition of claim 5, wherein the composition has less than about 25% degradation when stored at 25 ^ for one (1) month.

9. The composition of claim 1, wherein cardamonin is present in a concentration of about 0.0001% to about 5.0% w / w.

10. The composition of claim 1, wherein cardamonin is present in a concentration of about 0.0005% to about 2.0% w / w.

11. The composition of claim 1, wherein cardamonin is present in a concentration of 0.0007% to about 1.0% w / w.

12. The composition of claim 1, wherein cardamonin is present in a concentration of about 0.001% to about 0.75% w / w. 33 ^Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application 13. The composition of claim 1, wherein cardamonin is present in a concentration of about 0.5% w / w.

14. The composition of claim 1, wherein the composition is selected from a group consisting of: fluid, emulsion, encapsulation, suspension, solid, semi-solid, jelly, paste, gel, hydrogel, ointment, lotion, emulsion, cream, foam, mousse, liquid, spray, suspension, dispersion, powder, aerosol, color cosmetic, hair treatment, and any combination thereof.

15. The composition of claim 1, wherein the composition further comprises one or more excipients selected from a group consisting of: solvent, emulsifier, preservative, antioxidant, emollient, thickening agent, penetration enhancer, surfactant, diluent, filler, carrier, and / or pH control agent.

16. The composition of claim 15, wherein the preservative is an antimicrobial preservative or chelating agent.

17. The composition of claim 15, wherein the solvent is dimethyl isosorbide.

18. The composition of claim 1, wherein the composition further comprises one or more excipients selected from a group consisting of: water, dimethyl isosorbide, glycerin, caprylic / capric triglyceride, propanediol, sunflower seed oil, ethoxydiglycol, squalane, sodium acrylate copolymer, cetearyl alcohol, phenoxyethanol, glyceryl stearate, capryloyl glycerin / sebacic acid copolymer, diheptyl succinate, naringenin, lecithin, decylene glycol, pentylene glycol, cetearyl glucoside, shea butter, palmitic acid, arachidyl alcohol, behenyl alcohol, arachidyl glucoside, phenethyl alcohol, 1,2-hexanediol, hydrogenated olive oil, olea europaea (olive) fruit oil, olea europaea (olive) oil unsponifiables, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, citric acid, sodium acetylated hyaluronate, sodium hyaluronate crosspolymer, sodium phytate, hydrolyzed sodium hyaluronate, and ethylhexylglycerin.

19. The composition of claim 1, wherein the composition comprises about 50% to about 70% water (w / w) and about 10% to about 30% (w / w) dimethyl isosorbide. 34 ^Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application 20. The composition of claim 1, wherein the composition is: Ingredient %w / w Water 40 - 8035 ^Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application 21. A method of treating or preventing a topical condition in a subject by administration of a composition comprising an effective amount of cardamonin.

22. The method of claim 21, wherein the administration of the composition prevents fine lines or wrinkles on skin of the subject.

23. The method of claim 21, wherein the administration of the composition leads to supporting firmness and elasticity of skin of the subject.

24. The method of claim 21, wherein the administration of the composition leads to the prevention of skin and hair damaged by reactive oxygen species.

25. The method of claim 21, wherein the administration of the composition leads to protection from environment aggressors on skin.

26. The method of claim 21, wherein the administration of the composition leads to supporting skin elasticity.

27. The method of claim 21, wherein the topical condition is glycation.

28. The method of claim 21, wherein the administration of the composition leads increase in skin and / or hair resiliency.

29. The method of claim 21, wherein the administration of the composition leads to increase in elasticity of skin.

30. The method of claim 21, wherein the administration of the composition leads to prevention of skin damage.

31. The method of claim 21, wherein the composition is administered topically.

32. The method of claim 21, wherein the composition comprises an emulsion.

33. The method of claim 32, wherein the emulsion is an oil / water emulsion. 36 ^Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application 34. The method of claim 21, wherein the composition further comprises dimethyl isosorbide.

35. The method of claim 21, wherein the cardamonin is dissolved in dimethyl isosorbide.

36. The method of claim 35, wherein the composition is stable under storage for at least three (3) months.

37. The method of claim 35, wherein the composition has less than about 10% degradation when stored at 4 ^ for two (2) months.

38. The method of claim 35, wherein the composition has less than about 25% degradation when stored at 25 ^ for one (1) month.

39. The method of claim 21, wherein cardamonin is present in a concentration of about 0.0001% to about 5.0% w / w.

40. The method of claim 21, wherein cardamonin is present in a concentration of about 0.0005% to about 2.0% w / w.

41. The method of claim 21, wherein the cardamonin is present in a concentration of 0.0007% to about 1.0% w / w.

42. The method of claim 21, wherein cardamonin is present in a concentration of about 0.001% to about 0.75% w / w.

43. The method of claim 21, wherein cardamonin is present in a concentration of about 0.5% w / w.

44. The method of claim 21, wherein the composition is selected from a group consisting of: fluid, emulsion, encapsulation, suspension, solid, semi-solid, jelly, paste, gel, hydrogel, ointment, lotion, emulsion, cream, foam, mousse, liquid, spray, suspension, dispersion, powder, aerosol, color cosmetic, and any combination thereof. 37 ^Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application 45. The method of claim 21, wherein the composition further comprises one or more excipients selected from a group consisting of: solvent, emulsifier, preservative, antioxidant, emollient, thickening agent, penetration enhancer, surfactant, diluent, filler, carrier and / or pH control agent.

46. The method of claim 45, wherein the preservative is an antimicrobial preservative.

47. The method of claim 45, wherein the solvent is dimethyl isosorbide.

48. The method of claim 21, wherein the composition further comprises one or more excipients selected from a group consisting of: water, dimethyl isosorbide, glycerin, caprylic / capric triglyceride, propanediol, sunflower seed oil, ethoxydiglycol, squalane, sodium acrylate copolymer, cetearyl alcohol, phenoxyethanol, glyceryl stearate, capryloyl glycerin / sebacic acid copolymer, diheptyl succinate, naringenin, lecithin, decylene glycol, pentylene glycol, cetearyl glucoside, shea butter, palmitic acid, arachidyl alcohol, behenyl alcohol, arachidyl glucoside, phenethyl alcohol, 1,2-hexanediol, hydrogenated olive oil, olea europaea (olive) fruit oil, olea europaea (olive) oil unsponifiables, hydroxyethyl acrylate / sodium acryloyldimethyl taurate copolymer, citric acid, sodium acetylated hyaluronate, sodium hyaluronate crosspolymer, sodium phytate, hydrolyzed sodium hyaluronate, and ethylhexylglycerin.

49. The method of claim 21, wherein the composition comprises about 50% to about 70% water (w / w) and about 10% to about 30% (w / w) dimethyl isosorbide.

50. The method of claim 21, wherein the composition is: Ingredient %w / w38 ^Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application Cetearyl Alcohol 0 - 2 Phenoxyethanol 0 - 251. The composition of claim 1, wherein the composition is anhydrous.

52. The composition of claim 1, wherein the composition comprises oil as the only solvent.

53. The method of claim 21, wherein the composition is anhydrous.

54. The method of claim 21, wherein the composition comprises oil as the only solvent. 39 ^Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application 55. A method of modulating expression of one or more genes by administration of a composition comprising cardamonin, wherein at least one of the genes is related to a topical condition.

56. The method of claim 55, wherein the one or more genes are selected from a group consisting of: (i) MMP1, (ii) TNF, and (iii) IL37.

57. The method of claim 55, wherein the administration of the composition leads to down- regulation of TNF, IL37, and / or MMP1.

58. The method of claim 55, wherein the administration of the composition enhances anti- inflammatory activity.

59. The method of claim 55, wherein the administration of the composition enhances maintenance of skin barrier lipids.

60. The method of claim 55, wherein the administration of the composition enhances the maintenance of collagen network to prevent formation of fine lines and / or wrinkles in the skin.

61. The method of claim 55, wherein the administration of the composition results in downregulation of genes involved in degradation of collagen.

62. The method of claim 61, wherein the administration of the composition results in downregulation of expression and / or activity of MMP1.

63. The method of claim 58, wherein the administration of the composition results in downregulation of expression and / or activity of TNF and / or IL37.

64. The method of claim 55, wherein the administration of the composition to a subject leads to the treatment of prevention of a topical condition of the subject. 40 ^Attorney Docket No.: DEBU-018 / 01WO 37396 / 142 Patent Application 65. The method of claim 62, wherein the administration of the composition leads to at least about five (5) fold downregulation of MMP1.

66. The method of claim 63, wherein the administration of the composition leads to at least about ten (10) fold downregulation of TNF.

67. The method of claim 63, wherein the administration of the composition leads to at least about twenty (20) fold downregulation of IL37.

68. The method of claim 55, wherein the administration of composition alters one or more of a function related with the modulated genes, wherein the one or more function is selected from the group consisting of: (i) collagen degradation, (ii) inflammation, (iii) maintenance of collagen degradation, and (iv) any combination thereof.

69. The method of claim 55, wherein the composition further comprises a solvent.

70. The method of claim 55, wherein the solvent is selected from a group consisting of: dimethyl isosorbide, ethoxydiglycol, isopropyl lauryl sarcosinate, pentylene glycol, propanediol, 1,2-hexanediol, and / or butylene glycol. 41 ^